Forest Cipramil (citalopram) low level of drug-drug interactions is benefit for elderly, annual report says.
Executive Summary
FOREST TOUTS CIPRAMIL (CITALOPRAM) LOW LEVEL OF DRUG-DRUG INTERACTIONS in its recently-released annual report for fiscal 1997 (ended March 31). Forest filed an NDA for the selective serotonin reuptake inhibitor, licensed from the Danish firm H. Lundbeck, on May 12 under the brand name Cipramil ("The Pink Sheet" May 19, In Brief). "Recent data indicates that among the SSRIs, citalopram may be least likely to cause potential drug-drug interactions," Forest maintained in the annual report. Wyeth's promotions discussing Effexor's drug-drug interaction potential recently were cited by FDA's ad division.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth